Evofem Biosciences (NASDAQ:EVFM) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.34), MarketWatch Earnings reports.
NASDAQ:EVFM traded up $0.02 during trading hours on Thursday, reaching $3.58. 82 shares of the company were exchanged, compared to its average volume of 36,064. Evofem Biosciences has a twelve month low of $1.79 and a twelve month high of $12.90.
In related news, Director Thomas G. Lynch acquired 100,000 shares of Evofem Biosciences stock in a transaction on Wednesday, August 15th. The stock was bought at an average cost of $2.26 per share, for a total transaction of $226,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired 121,715 shares of company stock valued at $272,226 over the last 90 days. 3.40% of the stock is currently owned by company insiders.
EVFM has been the topic of a number of recent analyst reports. ValuEngine raised shares of Evofem Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Cantor Fitzgerald set a $9.00 price target on shares of Evofem Biosciences and gave the stock a “buy” rating in a report on Tuesday, October 30th. Oppenheimer set a $9.00 price target on shares of Evofem Biosciences and gave the stock a “buy” rating in a report on Wednesday. Finally, HC Wainwright set a $11.00 price target on shares of Evofem Biosciences and gave the stock a “buy” rating in a report on Monday, August 6th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $10.40.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.
Featured Article: Why do corrections happen?
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.